• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

2.680 -0.090 (-3.25%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 572,892
Open 2.720
Bid (Size) 2.570 (100)
Ask (Size) 2.990 (1,000)
Prev. Close 2.770
Today's Range 2.620 - 2.750
52wk Range 0.9100 - 4.200
Shares Outstanding 28,804,411
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
October 13, 2026
From Entera Bio Ltd.
Via GlobeNewswire
These stocks are moving in today's pre-market session ↗
October 09, 2026
Via Chartmill

Performance

52-Week Range 36.2% below 52-week high
2.680
0.9152W Low 4.2052W High
1 Week 5.0% below 1-week high
2.441W Low 2.821W High

Entera Bio Ltd. - Ordinary Shares (ENTX) traded between $0.91 and $4.20 over the past 52 weeks and last traded at $2.68, 36.2% below its 52-week high. Over the past week it ranged between $2.44 and $2.82.

Past 12 Months
+1.1%
-9.5%
+35.4%
+109.4%
+51.4%
+11.2%
1W +$0.03
1M -$0.28
3M +$0.70
6M +$1.40
YTD +$0.91
1Y +$0.27

ENTX was +11.2% over the past year, +109.4% over six months, +51.4% year to date, +1.1% in the last week.

12 Months vs Market
ENTX
+11.2%
DIA
+13.0%
SPY
+15.5%
QQQ
+18.3%
IWM
+10.4%

Over the past 12 months ENTX returned +11.2% versus DIA (Dow) +13.0%, SPY (S&P 500) +15.5%, QQQ (Nasdaq 100) +18.3% and IWM (Russell 2000) +10.4%.

Volume & Liquidity 0.31× 3-mo avg
Today 572,892 3-mo avg 1.9M
1W
773.2K
1M
623.6K
3M
1.9M
6M
1.5M
YTD
1.0M
1Y
830.4K

ENTX most recently traded 572,892 shares against a 3-month average daily volume of 1.9M.

More News

Read More
News headline image
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
October 08, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
October 06, 2026
From Entera Bio Ltd.
Via GlobeNewswire
Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise ↗
August 07, 2026
Via Chartmill
News headline image
Correction: Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera to Participate in Upcoming Fall Investor Conferences
August 27, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
August 18, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement ↗
August 13, 2026
Via MarketBeat
News headline image
Entera Announces Second Quarter 2026 Financial Results and Business Updates
August 07, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
August 04, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 31, 2026
From Entera Bio Ltd.
Via GlobeNewswire
Which stocks are moving on Monday? ↗
July 27, 2026
Via Chartmill
Curious about the most active stocks on Monday? ↗
July 27, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
July 27, 2026
Via Benzinga
Monday's session: top gainers and losers ↗
July 27, 2026
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
July 27, 2026
Via Chartmill
News headline image
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
July 27, 2026
From Entera Bio Ltd.
Via GlobeNewswire
What's going on in today's after hours session ↗
June 22, 2026
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
June 22, 2026
Via Chartmill
News headline image
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
June 22, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
June 16, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
June 15, 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
May 28, 2026
From Entera Bio Ltd.
Via GlobeNewswire
Get insights into the top gainers and losers of Friday's after-hours session. ↗
May 08, 2026
Via Chartmill

Frequently Asked Questions

Is Entera Bio Ltd. - Ordinary Shares publicly traded?
Yes, Entera Bio Ltd. - Ordinary Shares is publicly traded.
What exchange does Entera Bio Ltd. - Ordinary Shares trade on?
Entera Bio Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Entera Bio Ltd. - Ordinary Shares?
The ticker symbol for Entera Bio Ltd. - Ordinary Shares is ENTX on the Nasdaq Stock Market
What is the current price of Entera Bio Ltd. - Ordinary Shares?
The current price of Entera Bio Ltd. - Ordinary Shares is 2.680
When was Entera Bio Ltd. - Ordinary Shares last traded?
The last trade of Entera Bio Ltd. - Ordinary Shares was at 10/16/26 04:00 PM ET
What is the market capitalization of Entera Bio Ltd. - Ordinary Shares?
The market capitalization of Entera Bio Ltd. - Ordinary Shares is 77.20M
How many shares of Entera Bio Ltd. - Ordinary Shares are outstanding?
Entera Bio Ltd. - Ordinary Shares has 77M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap